BioPharmSignal logoBioPharmSignal

Biotech News

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon, Inc. (ANNX)Annexon, Inc.Earnings

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization Application (MAA) Under Review as the Potentially First Targeted Therapy for Guillain-Barré

Open original release

Related news

ANNXAnnexon, Inc.2026-03-30 20:01 EST

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

PRAXPraxis Precision Medicines2026-05-07 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-05-06 12:00 EST

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

NERVMinerva Neuroscience2026-05-05 12:00 EST

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

NBIXNeurocrine Biosciences2026-04-14 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

View all latest news

Annexon, Inc.

Annexon is a neuroscience company focused on complement biology and autoimmune or neuroinflammatory disease. Its platform is built around modulating immune pathways in the nervous system and beyond.

Recent company news

ANNXAnnexon, Inc.2026-05-27 12:00 EST

Annexon to Participate in Upcoming June Investor Conferences

ANNXAnnexon, Inc.2026-05-07 20:01 EST

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

ANNXAnnexon, Inc.2026-05-06 12:00 EST

Annexon to Present at the Bank of America Securities Health Care Conference 2026

ANNXAnnexon, Inc.2026-04-08 20:05 EST

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

ANNXAnnexon, Inc.2026-03-30 20:01 EST

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Stock data

Close
5.13 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States